Investment Analysts’ Updated EPS Estimates for September 14th (ADAG, ADUS, ANTO, AZTA, BIG, BLSH, CAPR, CBIO, CCI, CHTR)

Investment Analysts’ updated eps estimates for Monday, September 14th:

Adagene (NASDAQ:ADAG) had its buy rating reissued by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

Addus HomeCare (NASDAQ:ADUS) had its neutral rating reissued by analysts at Bank of America Corporation. The firm currently has a $125.00 target price on the stock, down from their previous target price of $140.00.

Antofagasta (LON:ANTO) was upgraded by analysts at Berenberg Bank to a buy rating. Berenberg Bank currently has GBX 4,400 price target on the stock.

Azenta (NASDAQ:AZTA) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $37.00 target price on the stock.

Big Technologies (LON:BIG) had its hold rating reiterated by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 105 target price on the stock.

Bullish (NYSE:BLSH) was upgraded by analysts at Compass Point from a neutral rating to a buy rating. Compass Point currently has $51.00 target price on the stock, up from their previous target price of $30.00.

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by analysts at B. Riley Financial, Inc. from a neutral rating to a buy rating. The firm currently has $21.00 target price on the stock, up from their previous target price of $5.00.

Crescent Biopharma (NASDAQ:CBIO) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $27.00 target price on the stock.

Crown Castle (NYSE:CCI) had its underweight rating reaffirmed by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $80.00 price target on the stock, down from their previous price target of $85.00.

Charter Communications (NASDAQ:CHTR) had its underperform rating reiterated by analysts at Wolfe Research. They currently have a $118.00 target price on the stock.

Chime Financial (NASDAQ:CHYM) was upgraded by analysts at Rothschild & Co Redburn from a neutral rating to a buy rating. Rothschild & Co Redburn currently has $46.00 target price on the stock.

Coinbase Global (NASDAQ:COIN) was upgraded by analysts at Compass Point from a sell rating to a neutral rating. Compass Point currently has $177.00 price target on the stock, up from their previous price target of $130.00.

Corbus Pharmaceuticals (NASDAQ:CRBP) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $35.00 target price on the stock.

California Resources (NYSE:CRC) had its outperform rating reaffirmed by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $77.00 target price on the stock.

Definium Therapeutics (NASDAQ:DFTX) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $66.00 target price on the stock.

Definium Therapeutics (NASDAQ:DFTX) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $70.00 price target on the stock.

Entain (LON:ENT) had its buy rating reissued by analysts at Berenberg Bank. The firm currently has a GBX 1,145 target price on the stock.

4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by analysts at Cantor Fitzgerald from a neutral rating to an overweight rating. They currently have $20.00 target price on the stock.

Fevertree Drinks (LON:FEVR) had its hold rating reissued by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 780 price target on the stock.

Genmab A/S (NASDAQ:GMAB) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $40.00 target price on the stock.

Hyperfine (NASDAQ:HYPR) had its buy rating reissued by analysts at BTIG Research. BTIG Research currently has a $2.00 price target on the stock.

IREN (NASDAQ:IREN) was upgraded by analysts at JPMorgan Chase & Co. from an underweight rating to an overweight rating. JPMorgan Chase & Co. currently has $65.00 target price on the stock, up from their previous target price of $46.00.

Invivyd (NASDAQ:IVVD) had its buy rating reissued by analysts at BTIG Research.

lululemon athletica (NASDAQ:LULU) had its hold rating reissued by analysts at Argus.

MARA (NASDAQ:MARA) had its underweight rating reiterated by analysts at JPMorgan Chase & Co.. They currently have a $11.00 price target on the stock, down from their previous price target of $13.00.

McKesson (NYSE:MCK) had its sector perform rating reissued by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $845.00 price target on the stock.

Oracle (NYSE:ORCL) had its buy rating reiterated by analysts at Argus. Argus currently has a $225.00 target price on the stock.

Pharming Group (NASDAQ:PHAR) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $37.00 price target on the stock.

PHINIA (NYSE:PHIN) was upgraded by analysts at Wall Street Zen from a hold rating to a buy rating.

Standard Life (LON:SDLF) had its buy rating reissued by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 1,072 target price on the stock.

Somnigroup International (NYSE:SGI) was upgraded by analysts at Stephens from an equal weight rating to an overweight rating. The firm currently has $80.00 target price on the stock, up from their previous target price of $66.00.

Sky Harbour Group (NYSE:SKYH) had its buy rating reiterated by analysts at BTIG Research. They currently have a $13.00 target price on the stock.

Solid Biosciences (NASDAQ:SLDB) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $25.00 price target on the stock.

Solventum (NYSE:SOLV) had its buy rating reiterated by analysts at BTIG Research. They currently have a $95.00 price target on the stock.

Scholar Rock (NASDAQ:SRRK) had its outperform rating reiterated by analysts at Wedbush. They currently have a $64.00 price target on the stock.

Transdigm Group (NYSE:TDG) had its hold rating reaffirmed by analysts at Melius Research. They currently have a $1,331.00 target price on the stock.

Telix Pharmaceuticals (NASDAQ:TLX) had its outperform rating reaffirmed by analysts at Wedbush. The firm currently has a $22.00 price target on the stock.

Trainline (LON:TRN) had its buy rating reiterated by analysts at Berenberg Bank. The firm currently has a GBX 350 price target on the stock.

Turn Therapeutics (NASDAQ:TTRX) had its sell rating reissued by analysts at WBB Securities. They currently have a $10.00 price target on the stock.

Ulta Beauty (NASDAQ:ULTA) had its buy rating reiterated by analysts at DA Davidson. The firm currently has a $625.00 target price on the stock.

Vodafone Group (NASDAQ:VOD) was upgraded by analysts at Wall Street Zen from a hold rating to a buy rating.

WesBanco (NASDAQ:WSBC) had its sector perform rating reaffirmed by analysts at Royal Bank Of Canada. The firm currently has a $44.00 price target on the stock.